Iovance BiotherapeuticsFRA:2LB -7.23%44 PB Ratio is 2.56 as of Jun. 26, 2026, which is 7% above its 10-year median of 2.39. GuruFocus rates FRA:2LB with a GF Score™ of 44/100 and a GF Value™ of €16.38 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,232 Biotechnology companies, Iovance Biotherapeutics ranks better than 53.25% on this metric.
The historical rank and industry rank for Iovance Biotherapeutics's PB Ratio or its related term are showing as below:
FRA:2LB'
s PB Ratio Range Over the Past 10 Years
Min: 0.72 Med: 2.39 Max: 7.36
Current: 2.55
During the past 13 years, Iovance Biotherapeutics's highest PB Ratio was 7.36. The lowest was 0.72. And the median was 2.39.
FRA:2LB's PB Ratio is ranked better than 53.25% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs FRA:2LB: 2.55
During the past 12 months, Iovance Biotherapeutics's average Book Value Per Share Growth Rate was -28.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -13.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -17.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -1.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Iovance Biotherapeutics was 45.00% per year. The lowest was -815.70% per year. And the median was 1.05% per year.
Back to Basics: PB Ratio
Iovance Biotherapeutics (FRA:2LB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Iovance Biotherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iovance Biotherapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Iovance Biotherapeutics (FRA:2LB) has a PB Ratio of 2.56 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Iovance Biotherapeutics and its competitors. This is near median its historical median of 2.39. Over the past decade, Iovance Biotherapeutics' PB Ratio has ranged from 0.72 to 7.36. According to the industry distribution chart, Iovance Biotherapeutics ranks #576 out of 1232 companies in the Biotechnology industry, placing it in the top 46.8%.
Is Iovance Biotherapeutics' PB Ratio too high?
Iovance Biotherapeutics' current PB Ratio of 2.56 is near median its 10-year median of 2.39. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 7.36. The Biotechnology industry median PB Ratio is 2.80. Iovance Biotherapeutics' value of 2.56 is 8.6% below this industry median. Based on the distribution chart, Iovance Biotherapeutics ranks #576 out of 1232 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' PB Ratio compare to HRMY and NRIX?
According to the Biotechnology industry distribution chart, Iovance Biotherapeutics ranks #576 out of 1232 companies for PB Ratio. This puts Iovance Biotherapeutics in the upper half of its industry. The industry median PB Ratio is 2.80. Iovance Biotherapeutics' value of 2.56 is 8.6% below this benchmark. Historically, Iovance Biotherapeutics' own PB Ratio has ranged from 0.72 to 7.36 over the past decade. While the company's 10-year median is 2.39 vs. the industry median of 2.80, Iovance Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iovance Biotherapeutics's current PB Ratio of 2.56 is 8.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Iovance Biotherapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iovance Biotherapeutics's current PB Ratio is 2.56, which is near median its own 10-year median of 2.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (FRA:2LB) is currently considered Possible Value Trap. The stock's GF Value™ is €16.38, compared to a current price of €3.66 — trading 77.7% below its estimated fair value. The current PB Ratio is 2.56, which is near median its 10-year median of 2.39 and 8.6% below the Biotechnology industry median of 2.80. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Iovance Biotherapeutics (FRA:2LB), the current PB Ratio is 2.56 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iovance Biotherapeutics (FRA:2LB) Overvalued in 2026?
Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued.
The current stock price of €3.66 is trading 77.7% below its estimated GF Value™ of €16.38.
GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.
Key valuation signals for FRA:2LB:
PB Ratio: 2.56 (near median its 10-year median of 2.39)
GF Value™: €16.38 vs. price of €3.66 (77.7% below fair value)
Industry Position: 8.6% below the Biotechnology median (#576 of 1232)
No single metric tells the full story. See the FRA:2LB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score
Get the complete analysis for FRA:2LB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2LB has been successfully added to your 
